• Home
• Investing

Investing

Precision Medicine's Missing Piece 

The Science of Getting Drugs Where They Need to Go

Investment Overview

CellMosaic is solving a fundamental problem in medicine: making powerful drugs work better by delivering them precisely where they're needed.

While pharmaceutical companies focus on developing new drugs, we provide the essential technology to deliver these medicines more effectively. Our platforms help researchers develop treatments that target diseased cells while sparing healthy tissue - potentially reducing side effects while maintaining therapeutic impact.

Through SEC-regulated crowdfunding (Regulation CF), it’s possible to own shares in CellMosaic. This investment approach opens access to the biotech sector in a unique way - instead of the traditional high-risk model of betting on single drug candidates, CellMosaic generates ongoing revenue by providing essential tools and services that many drug developers need. 

With pharmaceutical companies increasing their investment in our sector (ADC deal values up 400% since 2017), our established technology and revenue-generating business model offer investors a chance to participate in the growing drug delivery market without waiting years for a single drug to succeed or fail.

Key Points:

• Revenue-generating biotech company with $6.9M+ in sales and 500+ global customers

• Department of Defense-validated technology with 12 patents and 220+ proprietary processes

• Addressing a $200B+ market across cancer, diabetes, and other therapeutic areas

• Proven business model generating revenue at multiple stages of drug development

• Our products and technologies are trusted and adopted by prestigious institutions, including Stanford, Yale, and Massachusetts General Brigham

The Origins of Better Drug Delivery: How CellMosaic Started

In 2008, our team watched as cancer patients endured not just their disease, but also the severe side effects of their treatments. The sight of patients struggling with both cancer and chemotherapy toxicity sparked a fundamental question: Could we find a way to make powerful medicines more precise?

This question led to the founding of CellMosaic and the development of our AqueaTether® (AqT®) technology. Today, that same mission drives our work with over 500 research partners worldwide who use our tools to develop more targeted therapies.

The Technical Challenge

The core problem in drug delivery is precision. Traditional treatments, particularly in cancer therapy, affect both healthy and diseased cells. Antibody-drug conjugates (ADCs) offer a potential solution by acting as precision delivery systems. However, current ADCs face a significant limitation: poor stability in the bloodstream.

Our AqueaTether® technology addresses this stability challenge. By maintaining drug stability until the ADC reaches its target, the platform helps ensure medicines reach the intended cells while minimizing exposure to healthy tissue. This approach earned recognition from the Department of Defense's Breast Cancer Research Program as a breakthrough innovation for reducing drug toxicity while maintaining therapeutic efficacy.

Building a Complete Research Toolkit

We've developed several integrated platforms to support different aspects of drug development:

Real-World Applications

Our tools are currently supporting research across multiple therapeutic areas:

Cancer Treatment: Massachusetts General Brigham and the German Cancer Research Center (DKFZ) use our technology for specialized drug development programs. IBEX Biosciences employs our platforms for complex bioconjugation in cancer medicine development.

Addiction Treatment: The University of New Mexico is using our technology in NIH-funded vaccine development for opioid addiction, demonstrating applications beyond oncology.

Beyond Medicine: Our technology has found applications in unexpected areas, such as food safety testing at Reveal Foods, showing the versatility of our platforms.

Technical Specifications and Capabilities

Our technology portfolio includes:

• 12 global patents

• 220+ proprietary bioconjugation processes

• Validated manufacturing protocols

• Comprehensive quality control systems

The platforms support:

• Multiple conjugation chemistries

• Various payload types

• Flexible linker designs

• Scalable production processes

Impact on Drug Development

Researchers using our platforms have already generated new ADC lead products in various tumor types and reported several advantages:

• Reduced development time

• Enhanced targeting efficiency

• Simplified scale-up processes

These benefits translate directly to research outcomes. For example, Massachusetts General Brigham researchers were able to quickly validate their antibody in an ADC system with anti-metastatic activity in breast and pancreatic cancer mouse models, mediating a reduction in circulating tumor cells in the blood, without detectable, obvious toxicity to the mice or to normal tissues. Current ADCs primarily target solid tumors. Their ADC system may become the first few ADCs to specifically target circulating tumor cells to prevent further tumor cell disseminatioin (PNAS 2022, 43 (119), e2209563119). 

Future Development Areas

While our initial focus was cancer treatment, we plan to apply our technology to other therapeutic areas:

• Diabetes treatments

• Enzyme replacement therapy

• Gene delivery

The Scientific Foundation

Our approach builds on established principles in bioconjugation chemistry while introducing novel elements to improve stability and targeting. The core technology revolves around:

• Developing safer cancer drugs using advanced linker chemistry

• Enhanced drug stability in blood stream

• Increased efficacy with lower dosage

Research Support and Collaboration

We work alongside our research partners through:

• Commercial bioconjugation kits and reagents

• Technology licensing and partnering

• Product licensing and partnering

• Custom services and manufacturing 

From Lab to Impact

While the technical achievements are significant, we never lose sight of why this work matters. Recently, a researcher shared how our technology enabled them to develop a conjugate with significantly reduced off-target effects. This means patients in their clinical trials might avoid some of the harsh side effects typically associated with powerful medicines.

This is why we do this work. Every improvement in drug delivery technology represents a potential improvement in patient care - whether it's a parent able to maintain their daily routine during treatment or a patient experiencing fewer side effects while fighting their disease.

Looking Forward

The drug delivery landscape continues to evolve rapidly. The global ADC market alone is projected to reach $40 billion by 2029, with broader drug delivery applications representing a $200B+ opportunity. CellMosaic has positioned itself at the intersection of this growing market, having already generated $6.9M+ in revenue from our diverse customer base.

To give a sense of scale, Kadcyla (Roche Genentech) for treating HER2-positive metastatic breast cancer, $2.22B in sales 2023.

Investment in Scientific Progress

Our business model reflects our understanding of how scientific advancement happens:

• We provide essential research tools and services that generate immediate revenue

• We maintain strong IP protection with 12 patents and 220+ proprietary processes

• We create potential licensing opportunities as our partners' programs succeed

This approach has engaged leading institutions including Stanford, Yale, and Massachusetts General Brigham, validating both our technology and business strategy.

Why CellMosaic Presents a Unique Investment Opportunity

Unlike traditional biotech investments that bet on single drug candidates, CellMosaic generates revenue throughout the drug development process. Our technology platform serves as the foundation for multiple potential breakthroughs, diversifying risk while maximizing potential returns.

The metrics demonstrate our momentum:

• 500+ global customers across academia and industry

• 388 organizations using our research tools

• 104 custom manufacturing partnerships

• 400% increase in ADC deal values from 2017-2022

We are currently raising funds to: 

• Advance the synthesis and study of various AqT-linked safe drug assets for current and future ADC partnerships and licensing

• Development and manufacturing of AqT-ADCs for preclinical and clinical studies 

• Support the development, manufacturing, and expand global sales of other AqT-bioconjugate research products

For scientists and researchers considering an investment, you understand firsthand the critical need for better drug delivery systems. You've seen the limitations of current technologies and the impact on patient outcomes. By investing in CellMosaic, you're not just backing another biotech company – you're supporting the development of fundamental tools that could transform how we deliver life-saving medicines.

Join Us in Advancing Drug Delivery Science

When we started CellMosaic, we were driven by witnessing cancer patients struggling with devastating side effects. Today, that same mission drives our growth. Every research kit we ship, every manufacturing partnership we form, and every patent we secure brings us closer to our vision of more precise, effective treatments.

For those interested in joining our mission through investment, we offer an opportunity to participate in the advancement of drug delivery technology while potentially capturing value in this expanding market. Visit us on StartEngine to learn more about becoming part of CellMosaic's future in precision medicine.